<ul>
<li>MarketBeat 周报 – 7/10 - 7/14</li>
</ul>
<p>Caribou Biosciences, Inc. (NASDAQ:CRBU - 免费报告) - Leerink Partners 的研究分析师在 11 月 12 日向投资者发布的研究报告中上调了 Caribou Biosciences 2025 财年的每股收益（EPS）预期。Leerink Partners 的分析师 M. Foroohar 现在预计该公司在该年度的每股收益为（$1.38），高于之前的预期（$1.57）。市场普遍预计 Caribou Biosciences 当前全年的每股收益为（$1.64）。Leerink Partners 还对 Caribou Biosciences 2025 年第四季度的每股收益预期为（$0.30），2026 财年的每股收益预期为（$1.65），2027 财年的每股收益预期为（$1.73），2028 财年的每股收益预期为（$2.05）以及 2029 财年的每股收益预期为（$0.72）。</p>
<p>获取 <strong>Caribou Biosciences</strong> 的提醒：</p>
<p>其他研究分析师最近也发布了关于该公司的研究报告。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Caribou Biosciences 股票的 &#34;卖出（d-）&#34; 评级。花旗集团在 11 月 3 日的报告中将 Caribou Biosciences 的目标价从 $5.00 上调至 $8.00，并给予该股票 &#34;买入&#34; 评级。华尔街 Zen 在 8 月 24 日的研究报告中将 Caribou Biosciences 的评级从 &#34;卖出&#34; 上调至 &#34;持有&#34;。Truist Financial 在 11 月 4 日的报告中设定了 Caribou Biosciences 股票的目标价为 $7.00。最后，HC Wainwright 在 11 月 5 日的研究报告中将 Caribou Biosciences 股票的目标价从 $3.00 上调至 $9.00，并给予该股票 &#34;买入&#34; 评级。三位投资分析师对该股票给予了买入评级，一位分析师则给予了卖出评级。根据 MarketBeat.com 的数据，Caribou Biosciences 目前的共识评级为 &#34;适度买入&#34;，平均目标价为 $8.75。</p>
<ul>
<li>3 只生物科技股票值得长期投资</li>
</ul>
<p><strong>阅读我们关于 Caribou Biosciences 的最新研究报告</strong></p>
<h2>Caribou Biosciences 股价上涨 0.3%</h2>
<p>CRBU 股票在周一开盘价为 $1.99。该公司的市值为 $1.8601 亿，市盈率为 -1.17，贝塔值为 2.59。Caribou Biosciences 的 12 个月最低价为 $0.66，最高价为 $3.54。该股票的 50 日简单移动平均线为 $2.24，200 日简单移动平均线为 $1.76。</p>
<ul>
<li>辉瑞刚刚在这家生物科技公司投资了 2500 万美元</li>
</ul>
<p>Caribou Biosciences (NASDAQ:CRBU - 获取免费报告) 最近在 11 月 12 日发布了其财报。该公司报告的季度每股收益（EPS）为（$0.30），超过市场共识预期的（$0.36）$0.06。该公司本季度的收入为 $220 万，而市场共识预期为 $194 万。Caribou Biosciences 的净利润率为 -1690.45%，股本回报率为 -69.85%。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者和对冲基金最近调整了对该公司的持股。Cerity Partners LLC 在第一季度将其在 Caribou Biosciences 的持股增加了 163.6%。Cerity Partners LLC 目前拥有 40,722 股该公司的股票，价值 $37,000，此前在上个季度增持了 25,271 股。Nelson Capital Management LLC 在第一季度将其在 Caribou Biosciences 的持股增加了 31.1%。Nelson Capital Management LLC 目前拥有 85,020 股该公司的股票，价值 $78,000，此前在此期间增持了 20,162 股。Nuveen LLC 在第一季度购买了 Caribou Biosciences 的新股份，价值约 $302,000。Aberdeen Group plc 在第一季度将其在 Caribou Biosciences 的持股增加了 126.5%。Aberdeen Group plc 目前拥有 411,144 股该公司的股票，价值 $375,000，此前在此期间增持了 229,657 股。最后，Pale Fire Capital SE 在第一季度将其在 Caribou Biosciences 的持股增加了 7.2%。Pale Fire Capital SE 目前拥有 786,722 股该公司的股票，价值 $718,000，此前在上个季度增持了 52,518 股。对冲基金和其他机构投资者持有该公司 77.51% 的股份。</p>
<h2>关于 Caribou Biosciences</h2>
<p>（获取免费报告）</p>
<p>Caribou Biosciences, Inc. 是一家临床阶段的生物制药公司，专注于开发基因编辑的异体细胞疗法，以治疗美国及国际上的血液恶性肿瘤。其主要产品候选药物是 CB-010，一种异体抗 CD19 CAR-T 细胞疗法，目前正在进行 1 期临床试验，以治疗复发或难治性 B 细胞非霍奇金淋巴瘤。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Caribou Biosciences</li>
<li>经济报告在成功投资策略中的作用</li>
<li>4 只寒冷天气股票，适合冬季消费热潮</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投资股票</li>
<li>迪士尼股票下跌——收益能否为 YouTube TV 和解铺平道路？</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>Meta 的痛苦可能是你的机会：这是一个罕见的买入窗口吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JCVQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JCVQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 Caribou Biosciences 吗？</h2>
<p>在你考虑投资 Caribou Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前... 而 Caribou Biosciences 并不在名单上。</p>
<p>虽然 Caribou Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看五只股票</p>

CRBU

<p>Leerink Partners 将 Caribou Biosciences 的 2025 财年每股收益预期从（$1.57）上调至（$1.38）。当前年度的共识预期为（$1.64）。其他分析师的评级各不相同，整体共识为 “适度买入”，平均目标价为 $8.75。Caribou Biosciences 专注于基因编辑细胞疗法，其主要产品正在进行 1 期临床试验</p>

<ul>
<li>MarketBeat Week in Review – 7/10 - 7/14</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 7/10 - 7/14</li>
</ul>
</div><p>Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Research analysts at Leerink Partnrs raised their FY2025 EPS estimates for shares of Caribou Biosciences in a research note issued to investors on Wednesday, November 12th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($1.38) for the year, up from their prior estimate of ($1.57). The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share. Leerink Partnrs also issued estimates for Caribou Biosciences' Q4 2025 earnings at ($0.30) EPS, FY2026 earnings at ($1.65) EPS, FY2027 earnings at ($1.73) EPS, FY2028 earnings at ($2.05) EPS and FY2029 earnings at ($0.72) EPS.</p>
<div class="lb-trans"><p>Caribou Biosciences, Inc. (NASDAQ:CRBU - 免费报告) - Leerink Partners 的研究分析师在 11 月 12 日向投资者发布的研究报告中上调了 Caribou Biosciences 2025 财年的每股收益（EPS）预期。Leerink Partners 的分析师 M. Foroohar 现在预计该公司在该年度的每股收益为（$1.38），高于之前的预期（$1.57）。市场普遍预计 Caribou Biosciences 当前全年的每股收益为（$1.64）。Leerink Partners 还对 Caribou Biosciences 2025 年第四季度的每股收益预期为（$0.30），2026 财年的每股收益预期为（$1.65），2027 财年的每股收益预期为（$1.73），2028 财年的每股收益预期为（$2.05）以及 2029 财年的每股收益预期为（$0.72）。</p>
</div><p>Get <strong>Caribou Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Caribou Biosciences</strong> 的提醒：</p>
</div><p>Other research analysts have also recently issued research reports about the company. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Caribou Biosciences in a research note on Wednesday, October 8th. Citigroup lifted their price objective on Caribou Biosciences from $5.00 to $8.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, November 3rd. Wall Street Zen raised Caribou Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Sunday, August 24th. Truist Financial set a $7.00 price target on shares of Caribou Biosciences in a report on Tuesday, November 4th. Finally, HC Wainwright lifted their price target on shares of Caribou Biosciences from $3.00 to $9.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, November 5th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Caribou Biosciences presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $8.75.</p>
<div class="lb-trans"><p>其他研究分析师最近也发布了关于该公司的研究报告。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Caribou Biosciences 股票的 &#34;卖出（d-）&#34; 评级。花旗集团在 11 月 3 日的报告中将 Caribou Biosciences 的目标价从 $5.00 上调至 $8.00，并给予该股票 &#34;买入&#34; 评级。华尔街 Zen 在 8 月 24 日的研究报告中将 Caribou Biosciences 的评级从 &#34;卖出&#34; 上调至 &#34;持有&#34;。Truist Financial 在 11 月 4 日的报告中设定了 Caribou Biosciences 股票的目标价为 $7.00。最后，HC Wainwright 在 11 月 5 日的研究报告中将 Caribou Biosciences 股票的目标价从 $3.00 上调至 $9.00，并给予该股票 &#34;买入&#34; 评级。三位投资分析师对该股票给予了买入评级，一位分析师则给予了卖出评级。根据 MarketBeat.com 的数据，Caribou Biosciences 目前的共识评级为 &#34;适度买入&#34;，平均目标价为 $8.75。</p>
</div><ul>
<li>3 Biotech Stocks to Buy for Long-Term Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只生物科技股票值得长期投资</li>
</ul>
</div><p><strong>Read Our Latest Research Report on Caribou Biosciences</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Caribou Biosciences 的最新研究报告</strong></p>
</div><h2>Caribou Biosciences Trading Up 0.3%</h2>
<div class="lb-trans"><h2>Caribou Biosciences 股价上涨 0.3%</h2>
</div><p>CRBU stock opened at $1.99 on Monday. The stock has a market capitalization of $186.01 million, a PE ratio of -1.17 and a beta of 2.59. Caribou Biosciences has a 12-month low of $0.66 and a 12-month high of $3.54. The stock's 50 day simple moving average is $2.24 and its 200 day simple moving average is $1.76.</p>
<div class="lb-trans"><p>CRBU 股票在周一开盘价为 $1.99。该公司的市值为 $1.8601 亿，市盈率为 -1.17，贝塔值为 2.59。Caribou Biosciences 的 12 个月最低价为 $0.66，最高价为 $3.54。该股票的 50 日简单移动平均线为 $2.24，200 日简单移动平均线为 $1.76。</p>
</div><ul>
<li>Pfizer Just Invested $25 million In This Biotech</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞刚刚在这家生物科技公司投资了 2500 万美元</li>
</ul>
</div><p>Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its earnings results on Wednesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.06. The firm had revenue of $2.20 million for the quarter, compared to the consensus estimate of $1.94 million. Caribou Biosciences had a negative net margin of 1,690.45% and a negative return on equity of 69.85%.</p>
<div class="lb-trans"><p>Caribou Biosciences (NASDAQ:CRBU - 获取免费报告) 最近在 11 月 12 日发布了其财报。该公司报告的季度每股收益（EPS）为（$0.30），超过市场共识预期的（$0.36）$0.06。该公司本季度的收入为 $220 万，而市场共识预期为 $194 万。Caribou Biosciences 的净利润率为 -1690.45%，股本回报率为 -69.85%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the business. Cerity Partners LLC lifted its position in shares of Caribou Biosciences by 163.6% in the first quarter. Cerity Partners LLC now owns 40,722 shares of the company's stock valued at $37,000 after acquiring an additional 25,271 shares in the last quarter. Nelson Capital Management LLC raised its stake in Caribou Biosciences by 31.1% during the 1st quarter. Nelson Capital Management LLC now owns 85,020 shares of the company's stock valued at $78,000 after purchasing an additional 20,162 shares during the period. Nuveen LLC purchased a new position in Caribou Biosciences in the 1st quarter worth approximately $302,000. Aberdeen Group plc boosted its stake in Caribou Biosciences by 126.5% in the 1st quarter. Aberdeen Group plc now owns 411,144 shares of the company's stock worth $375,000 after purchasing an additional 229,657 shares during the period. Finally, Pale Fire Capital SE grew its holdings in Caribou Biosciences by 7.2% during the 1st quarter. Pale Fire Capital SE now owns 786,722 shares of the company's stock valued at $718,000 after buying an additional 52,518 shares in the last quarter. Hedge funds and other institutional investors own 77.51% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近调整了对该公司的持股。Cerity Partners LLC 在第一季度将其在 Caribou Biosciences 的持股增加了 163.6%。Cerity Partners LLC 目前拥有 40,722 股该公司的股票，价值 $37,000，此前在上个季度增持了 25,271 股。Nelson Capital Management LLC 在第一季度将其在 Caribou Biosciences 的持股增加了 31.1%。Nelson Capital Management LLC 目前拥有 85,020 股该公司的股票，价值 $78,000，此前在此期间增持了 20,162 股。Nuveen LLC 在第一季度购买了 Caribou Biosciences 的新股份，价值约 $302,000。Aberdeen Group plc 在第一季度将其在 Caribou Biosciences 的持股增加了 126.5%。Aberdeen Group plc 目前拥有 411,144 股该公司的股票，价值 $375,000，此前在此期间增持了 229,657 股。最后，Pale Fire Capital SE 在第一季度将其在 Caribou Biosciences 的持股增加了 7.2%。Pale Fire Capital SE 目前拥有 786,722 股该公司的股票，价值 $718,000，此前在上个季度增持了 52,518 股。对冲基金和其他机构投资者持有该公司 77.51% 的股份。</p>
</div><h2>About Caribou Biosciences</h2>
<div class="lb-trans"><h2>关于 Caribou Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.</p>
<div class="lb-trans"><p>Caribou Biosciences, Inc. 是一家临床阶段的生物制药公司，专注于开发基因编辑的异体细胞疗法，以治疗美国及国际上的血液恶性肿瘤。其主要产品候选药物是 CB-010，一种异体抗 CD19 CAR-T 细胞疗法，目前正在进行 1 期临床试验，以治疗复发或难治性 B 细胞非霍奇金淋巴瘤。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Caribou Biosciences</li>
<li>The Role Economic Reports Play in a Successful Investment Strategy</li>
<li>4 Cold-Weather Stocks to Buy as Winter Spending Heats Up</li>
<li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li>
<li>Disney Stock Drops—Will Earnings Pave Way for a YouTube TV Truce?</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Caribou Biosciences</li>
<li>经济报告在成功投资策略中的作用</li>
<li>4 只寒冷天气股票，适合冬季消费热潮</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投资股票</li>
<li>迪士尼股票下跌——收益能否为 YouTube TV 和解铺平道路？</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>Meta 的痛苦可能是你的机会：这是一个罕见的买入窗口吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JCVQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=CRBU"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Caribou Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Caribou Biosciences 吗？</h2>
</div><p>Before you consider Caribou Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Caribou Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Caribou Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前... 而 Caribou Biosciences 并不在名单上。</p>
</div><p>While Caribou Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Caribou Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看五只股票</p>
</div>

Leerink Partners 发布了对 Caribou Biosciences 的 2025 财年收益预测